Toronto, Canada – November 8, 2025 – Renellence Inc. is pleased to announce that Croma-Pharma’s Revitalis has received approval from Health Canada for use in Canada as an injectable Class III medical device.
Revitalis is a non-crosslinked hyaluronic acid skin booster formulated to support skin hydration, elasticity, and overall skin quality. Designed for use in the face, including delicate areas, Revitalis represents Croma-Pharma’s expansion into skin-boosting injectable solutions focused on improving skin appearance rather than volumization.
With Health Canada approval in place, Revitalis expands the range of regulated aesthetic options available to Canadian healthcare professionals. Its formulation reflects a growing focus on skin quality treatments that prioritize hydration, texture, and luminosity while supporting safe and controlled clinical application.
Through the introduction of Croma Revitalis, Renellence continues to support Canadian practitioners by providing access to products that meet regulatory requirements and align with evolving approaches to aesthetic care.